MiNK Therapeutics is a biopharmaceutical company developing allogeneic iNKT cell therapies and immune technologies for treatment.
MiNK Therapeutics's investors include National Institute of Allergy and Infectious Diseases, GKCC.
MiNK Therapeutics is headquartered in New York, United States.
MiNK Therapeutics is a biopharmaceutical company developing allogeneic iNKT cell therapies and immune technologies for treatment.
MiNK Therapeutics is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"MiNK Therapeutics — Funding & Investors." VCBacked, June 2, 2025, https://www.vcbacked.co/company/mink-therapeutics. Accessed November 13, 2026.
VCBacked. (2025). MiNK Therapeutics — Funding & Investors. Retrieved November 13, 2026, from https://www.vcbacked.co/company/mink-therapeutics
{{cite web |title=MiNK Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/mink-therapeutics |website=VCBacked |access-date=November 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at MiNK Therapeutics? Request a listing update